Literature DB >> 19104086

Use of the Valsalva manoeuvre in the prehospital setting: a review of the literature.

G Smith1, A Morgans, M Boyle.   

Abstract

BACKGROUND: The Valsalva manoeuvre (VM) is used in the prehospital setting as a first-line treatment for managing haemodynamically stable supraventricular tachycardia (SVT) in the form of atrioventricular nodal re-entrant tachycardia (AVNRT) and atrioventricular re-entrant tachycardia (AVRT). The hospital-based use of this technique is supported by a number of published studies, but the performance and efficacy of the VM in the prehospital setting has not been examined.
METHODS: A review of the literature via electronic databases was conducted. Six clinical studies examining the technique and efficacy of the VM in arrhythmia reversion were identified. No prehospital studies were identified. Significant variation in the practical application of the VM and its efficacy was noted.
RESULTS: The literature identified three primary elements of the technique which affected its efficacy in reversion of SVT: a pressure of 40 mm Hg, the supine position and duration of 15 s. The efficacy of the VM in reversion of SVT is difficult to quantify in some literature owing to variations in technique and clinical application. The VM appears to be more successful than carotid sinus massage and ice-to-face techniques, and is inherently safe across all age groups.
CONCLUSION: This review has shown that a standard of performance of the VM technique is defined within the medical literature, but no evidence exists to determine its efficacy or use in the prehospital setting. A prehospital study is therefore required to affirm the VM as part of prehospital clinical practice guidelines for SVT.

Entities:  

Mesh:

Year:  2009        PMID: 19104086     DOI: 10.1136/emj.2008.061572

Source DB:  PubMed          Journal:  Emerg Med J        ISSN: 1472-0205            Impact factor:   2.740


  8 in total

Review 1.  Managing collapsed or seriously ill participants of ultra-endurance events in remote environments.

Authors:  Martin D Hoffman; Ian R Rogers; Jeremy Joslin; Chad A Asplund; William O Roberts; Benjamin D Levine
Journal:  Sports Med       Date:  2015-02       Impact factor: 11.136

Review 2.  Effectiveness of the Valsalva Manoeuvre for reversion of supraventricular tachycardia.

Authors:  Gavin D Smith; Meagan M Fry; David Taylor; Amee Morgans; Kate Cantwell
Journal:  Cochrane Database Syst Rev       Date:  2015-02-18

3.  Evaluation of pre-hospital use of a valsalva assist device in the emergency treatment of supraventricular tachycardia [EVADE]: a randomised controlled feasibility trial.

Authors:  Andrew Appelboam; Jonathan Green; Paul Ewings; Sarah Black
Journal:  Pilot Feasibility Stud       Date:  2020-05-25

4.  Comparison of Various Vagal Maneuvers for Supraventricular Tachycardia by Network Meta-Analysis.

Authors:  Edward Pei-Chuan Huang; Chi-Hsin Chen; Cheng-Yi Fan; Chih-Wei Sung; Pei Chun Lai; Yen Ta Huang
Journal:  Front Med (Lausanne)       Date:  2022-02-03

5.  A cross-sectional study of Victorian Mobile Intensive Care Ambulance Paramedics knowledge of the Valsalva Manoeuvre.

Authors:  Gavin Smith; Malcolm J Boyle
Journal:  BMC Emerg Med       Date:  2009-12-14

Review 6.  [Adult advanced life support].

Authors:  Jasmeet Soar; Bernd W Böttiger; Pierre Carli; Keith Couper; Charles D Deakin; Therese Djärv; Carsten Lott; Theresa Olasveengen; Peter Paal; Tommaso Pellis; Gavin D Perkins; Claudio Sandroni; Jerry P Nolan
Journal:  Notf Rett Med       Date:  2021-06-08       Impact factor: 0.826

7.  Randomised Evaluation of modified Valsalva Effectiveness in Re-entrant Tachycardias (REVERT) study.

Authors:  Andrew Appelboam; Adam Reuben; Clifford Mann; Trudie Lobban; Paul Ewings; Jonathan Benger; Jane Vickery; Andrew Barton; James Gagg
Journal:  BMJ Open       Date:  2014-03-12       Impact factor: 2.692

8.  Head Down Deep Breathing for Cardioversion of Paroxysmal Supraventricular Tachycardia.

Authors:  Steven Hoon Chin Lim; Shieh Mei Lai; Kelvin Cheok Keng Wong
Journal:  Case Rep Emerg Med       Date:  2018-09-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.